ArticleCancer2021

A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Gautam Borthakur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.